This hypothesis prompted us to test if CD69high CLL cells without p53 alterations (CD69 expression > 30%)[43] could be sensitized to bendamustine with some therapeutic strategy. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.